Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC0114-0006 in subjects with active rheumatoid arthritis Ensayo aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia clínica de NNC0114-0006 en sujetos con artritis reumatoide activa
To evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid arthritis (RA) on background ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
An extension trial comparing safety and efficacy of NN5401 with insulin glargine in subjects with type 2 diabetes Ensayo de extensión para comparar la eficacia y seguridad de NN5401 frente a insulina glargina en sujetos con Diabetes tipo 2
El objetivo principal es investigar la seguridad y la tolerabilidad a largo plazo de SIAC. Esto se realiza comparando SIAC con insulina glargina después de 52 semanas de tratamiento (26 semanas de tra...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, single-dose, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC 0142-0000-0002 in subjects with active rheumatoid arthritis
To evaluate the change in disease activity following a single subcutaneous (s.c.) dose of NNC 142-0002 compared to placebo in subjects with active rheumatoid arthritis (RA) on background methotrexate ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir and OAD treatment, in subjects with type 2 diabetes
To investigate if IAsp added step-wise (1-2-3) in a Basic regimen (according to the largest meal, and titrated based mainly on pre-meal SMPG) is equivalent to IAsp added step-wise (1-2-3) in an Advanc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus Ensayo clínico para comparar el control glucémico y la seguridad de insulina degludec/liraglutida (IDegLira) frente a insulina glargina (IGlar) como tratamiento complementario a SGLT2i en sujetos con diabetes mellitus tipo 2
To confirm the effect of insulin degludec/liraglutide (IDegLira) in terms of glycaemic control in subjects with type 2 diabetes mellitus (T2DM) on previous treatment with sodium-glucose cotransporter ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A 52-week randomised, controlled, open label,multicentre, multinational treat-to target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin ± treatment with metformin, ± pioglitazone in subjects with type 2 diabetes currently treated with insulin qualifying for intensified treatment
To confirm the efficacy of SIBA + insulin aspart ± OAD(s) in controlling glycaemia with respect to change from baseline in HbA1c after 52 weeks of treatment. This is done by comparing the difference i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk Pharma S.A
MAJ Il y a 5 ans
A multi-centre, open-labelled, randomised, two-group parallel, treat-to-target trial comparing the weight change in overweight and obese subjects with type 2 diabetes after 26 weeks of treatment with insulin detemir once daily versus insulin NPH once daily, both with insulin aspart in the mealtime. (PREDICTIVE-BMI study)
To compare the weight change during 26 weeks of treatment with insulin detemir versus NPH insulin in obese or overweight type 2 diabetic subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only
To compare the effects of three dose levels of once-daily oral semaglutide (3, 7 and 14 mg) versus once-daily placebo on glycaemic control in subjects with type 2 diabetes mellitus treated with diet a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Treatment intensification with biphasic insulin aspart 30 in subjects with type 2 diabetes inadequately controlled on sitagliptin and metformin
To compare the efficacy in terms of glycaemic control of biphasic insulin aspart 30 (BIAsp 30) twice daily + sitagliptin + metformin, BIAsp 30 twice daily + metformin and BIAsp 30 once daily + sitagli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination with Insulin Glargine and Metformin in Adults with Type 2 Diabetes
To confirm efficacy of treatment with meal time faster-acting insulin aspart (FIAsp) in terms of glycaemic control measured by glycosylated haemoglobin (HbA1c) after 26 weeks of randomised treatment, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
11
12
13
14
15
16
17
18
19
20
Suivant